| Expression pattern: |
UP |
| Associated gene: |
SRSF2, SLC7A11, EIF4A3, AGO2 |
| Associated microRNA: |
miR-143-5p |
| Biological function: |
promotes proliferation, migration, invasion and metastasis; confers ferroptosis resistance (inhibits ferroptosis) |
| Molecular mechanism: |
ceRNA sponging of miR-143-5p to upregulate SRSF2; EIF4A3 promotes circCNOT6L biogenesis; SRSF2-dependent alternative splicing of SLC7A11 increases SLC7A11 and suppresses ferroptosis |
| Biological pathway or process: |
ferroptosis (inhibits); metastasis (promotes); migration (promotes); invasion (promotes); EMT (promotes); proliferation (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining; Western Blot; RNA 3D-structure prediction; Flow Cytometry（Non-apoptosis/cycle） |
| Clinical significance: |
circCNOT6L expression is higher in metastatic lymph nodes/mPCa and correlates with metastasis/high Gleason score; detected in urine across BPH, localized PCa and metastatic PCa cohorts |
| Description: |
circCNOT6L is up-regulated in prostate cancer, especially in metastatic settings, and promotes proliferation, EMT-associated migration/invasion, and metastasis. It functions mainly in the cytoplasm as a ceRNA that sponges miR-143-5p to upregulate SRSF2, which enhances SLC7A11 splicing/expression to suppress ferroptosis, contributing to malignant progression; EIF4A3 facilitates its biogenesis. |
| Confidence score: |
0.8446 |